Latest News

Nirogacestat shows significant long-term benefits in treating desmoid tumors, improving survival rates and patient outcomes with manageable side effects.

Jonathan Strosberg, MD, details findings with 212Pb-DOTAMTATE in patients with gastroenteropancreatic neuroendocrine tumors from the ALPHAMEDIX-02 trial.

A study reveals that obesity and sex significantly influence liver recurrence and survival rates in pancreatic cancer patients post-surgery.

During a live event, Randy F. Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma.

The COMPETE trial reveals ITM-11 significantly improves progression-free and overall survival in patients with gastroenteropancreatic neuroendocrine tumors.

A groundbreaking study reveals 212Pb-DOTAMTATE's promising efficacy and safety in treating advanced gastroenteropancreatic neuroendocrine tumors.

New data reveals VCN-01 enhances survival and response rates in metastatic pancreatic cancer when combined with standard chemotherapy, promising future trials.

A novel treatment combining EIK1001 with pembrolizumab shows promising response rates in advanced non-small cell lung cancer, enhancing patient outcomes.

Emerging research highlights the rising incidence of early-onset neuroendocrine tumors, revealing unique challenges and symptom burdens in younger patients.

New research highlights narsoplimab's potential to significantly reduce mortality in high-risk patients with thrombotic microangiopathy after stem cell transplants.

Zenocutuzumab gains FDA breakthrough therapy designation for advanced cholangiocarcinoma, showcasing promising trial results and potential targeted treatment options.

Discover the latest breakthroughs in oncology, including FDA approvals, clinical trial results, and innovative therapies shaping cancer treatment today.

A recent study reveals significant racial differences in renal cell carcinoma histology and outcomes, highlighting the need for ancestry-informed kidney care strategies.

A clinical trial reveals no survival benefit from stem cell transplantation in lower-risk MDS patients, highlighting the need for improved posttransplant outcomes.

The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes and improving patient outcomes.

Over 200 oncologists voted on their preferred treatment in second- and third-line relapsed/refractory chronic lymphocytic leukemia.

Revumenib gains FDA approval for treating relapsed mNPM1 AML, showcasing promising efficacy and safety data from the AUGMENT-101 trial.

The FDA fast tracks MT-125, a promising new treatment for glioblastoma, enhancing patient care and expediting drug development.

New research reveals that sustained MRD negativity after ASCT allows safe discontinuation of lenalidomide maintenance in multiple myeloma patients.

During a live event, Anthony B. El-Khoueiry, MD, discussed downstaging for transplant and evolving frontline systemic therapies in advanced HCC.

FDA approves new combinations for multiple myeloma treatment, enhancing survival rates and addressing unmet needs in patient care.

During a live event, Wade T. Iams, MD, MSCI, examined outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer.

The FDA fast-tracks pamlectabart tismanitin, a promising treatment for relapsed multiple myeloma, enhancing its development and review process.

A phase 1 trial reveals camu camu's safety and potential benefits in melanoma and NSCLC patients undergoing immune checkpoint therapy.

Phase 2 trial CALYPSO reveals no improvement in outcomes for advanced renal cell carcinoma with savolitinib addition, prompting reevaluation of treatment strategies.

New findings reveal that adding sapanisertib to weekly paclitaxel significantly improves progression-free survival in advanced ovarian cancer patients.

A recent study reveals that alternative donors for hematopoietic cell transplants yield similar success rates as fully matched donors, enhancing patient outcomes.

During a live event, Lori Wirth, MD, discussed next steps for treating a patient with progressive, radioactive iodine–refractory differentiated thyroid cancer.

Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.

FDA prioritizes review of enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, showing promising results in reducing recurrence and mortality.

Triplet therapy of ciforadenant, nivolumab, and ipilimumab shows safety but lacks efficacy in advanced clear cell kidney cancer.